LONDON – British billionaire Jim Mellon said he is planning to take his life extension company Juvenescence public in the next six to 12 months.
Founded in October 2016, Juvenescence is investing in a wide range of anti-ageing therapies that it thinks have the potential to extend the human life. One of those investments is Insilico Medicine, which is aiming to use artificial intelligence for drug discovery. It has also backed AgeX Therapeutics, a California-headquartered firm trying to create stem cells that can regenerate ageing tissue, and LyGenesis, which wants to develop a technology that uses lymph nodes as bioreactors to regrow replacement organs.
Speaking to CNBC on Monday from the Spanish island of Ibiza via Zoom, Mellon, who is the chairman of Juvenescence, said: “We have been approached by multiple investment banks and we have identified the investment banks we want to work with.”
Mellon, who has been previously called Britain’s “answer to Warren Buffett,” added: “We are likely, within the next six months to a year, to be a public company assuming everything goes well and markets don’t collapse etc.” The listing will probably be in the U.S. although no firm decision has been made.
The IPO (initial public offering) appears to be running behind schedule; the Financial Times reported in June 2018 that it would happen at some point in 2019.
Juvenescence, which has 29 employees in London, has raised about $170 million privately and Mellon said it still has a “fair amount of money left in the bank.” Other billionaires, including Mike Cannon-Brookes, the co-founder of Australian software firm Atlassian, and NEX Group founder Michael Spencer, have invested in the company.
Mellon, who profited in the 1990s from Russian privatization and areas like mining, said there’s a “good chance” that people his age will live another